MHRA – Page 182 – Pharma.Tips

Assay Oos in ear drop manufacturing: manufacturing vs lab root cause decision tree

Root Cause Analysis for Out of Specification Assays in Ear Drop Manufacturing Out of Specification (OOS) assays can pose significant challenges in the manufacturing of pharmaceutical products, particularly for delicate…

Ph Drift after packaging change: packaging compatibility and shelf-life justification

Investigating pH Drift Post-Packaging Change: Strategies for Ensuring Compatibility and Stability In the pharmaceutical manufacturing environment, a pH drift following a packaging change can present significant challenges, particularly regarding product…

Phase Separation during method transfer: sampling and mixing controls for QA review

Analyzing Phase Separation Occurrences During Method Transfer: A Comprehensive Guide for Quality Assurance Review Phase separation in pharmaceutical manufacturing can significantly impact quality, particularly during method transfer processes. This article…

Viscosity Drift during inspection readiness: GMP documentation for FDA/EMA/MHRA review

Understanding and Addressing Viscosity Drift for Regulatory Compliance In the realm of pharmaceutical manufacturing, one common challenge encountered during the inspection readiness phase is viscosity drift. This deviation can lead…

Texture Grittiness Complaint after packaging change: sampling and mixing controls for QA review

Investigation into Texture Grittiness Complaints Following a Packaging Change In pharmaceutical manufacturing, quality complaints such as texture grittiness can indicate underlying issues that can impact product quality and patient satisfaction.…

Tube Leakage Complaint during method transfer: packaging compatibility and shelf-life justification

Investigation of Tube Leakage Complaints during Method Transfer: Ensuring Packaging Compatibility and Justifying Shelf Life In the realm of pharmaceutical manufacturing, particularly within the domain of dosage forms, tube leakage…

E&L Failure after supplier change: sampling and mixing controls for QA review

E&L Failures Post-Supplier Change: Implementing Robust Sampling and Mixing Controls When a supplier is changed in pharmaceutical manufacturing, it can lead to significant risks, including extractables and leachables (E&L) failures.…

Assay Oos after supplier change: GMP documentation for FDA/EMA/MHRA review

Investigating Assay Out of Specification Following Supplier Change in GMP Environments In the complex landscape of pharmaceutical manufacturing, a change in supplier can introduce unexpected variability that may culminate in…

Microbial Limits Failure during method transfer: QMS trending and complaint handling expectations

Addressing Microbial Limits Failures During Method Transfer: A Comprehensive Investigation Guide Challenges in microbial limit testing are frequent topics of concern in pharmaceutical manufacturing, particularly during method transfer processes. When…

Texture Grittiness Complaint after supplier change: QMS trending and complaint handling expectations

Managing Texture Grittiness Complaints: A Comprehensive Guide for Pharmaceutical Investigations Pharmaceutical professionals are often confronted with complaints regarding product quality, particularly texture grittiness in dosage forms after a change in…

Hold Time Bioburden Rise after supplier change: investigation steps with CAPA evidence

Investigating Hold Time Bioburden Increase Following a Supplier Change: Effective Steps for CAPA In the fast-paced world of pharmaceutical manufacturing, changes in suppliers can lead to unforeseen challenges, including Quality…

Microbial Limits Failure in dental gel manufacturing: packaging compatibility and shelf-life justification

Investigating Microbial Limits Failure in Dental Gel Manufacturing: Insights on Packaging Compatibility and Shelf-Life Justification The pharmaceutical manufacturing industry faces numerous challenges, particularly when producing dental gels where microbial limits…